Cargando…

Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis

SIMPLE SUMMARY: Systemic mastocytosis (SM) is a clonal haematopoietic stem cell disease typically characterized by the expansion and accumulation of neoplastic mast cells carrying the activating KIT D816V as a driver mutation. Multilineage involvement of haematopoiesis by this KIT mutation, particul...

Descripción completa

Detalles Bibliográficos
Autores principales:	González-López, Oscar, Muñoz-González, Javier I., Orfao, Alberto, Álvarez-Twose, Iván, García-Montero, Andrés C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139197/ https://www.ncbi.nlm.nih.gov/pubmed/35626091 http://dx.doi.org/10.3390/cancers14102487

Ejemplares similares

Altered innate immune profile in blood of systemic mastocytosis patients
por: Pérez‐Pons, Alba, et al.
Publicado: (2022)

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis
por: Dasilva-Freire, Noelia, et al.
Publicado: (2019)

Serum Tryptase Monitoring in Indolent Systemic Mastocytosis: Association with Disease Features and Patient Outcome
por: Matito, Almudena, et al.
Publicado: (2013)

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
por: Piris-Villaespesa, Miguel, et al.
Publicado: (2020)

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Mastocytosis presenting with mast cell‐mediator release‐associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features
por: Rama, Tiago Azenha, et al.
Publicado: (2022)

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes
por: González-de-Olano, David, et al.
Publicado: (2016)

COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
por: Giannetti, Matthew P., et al.
Publicado: (2021)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas
por: González-Tablas, María, et al.
Publicado: (2021)

Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
por: Valent, Peter, et al.
Publicado: (2020)

Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021
por: Lange, Magdalena, et al.
Publicado: (2021)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Validation of the Mayo alliance prognostic system for mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2019)

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
por: Gotlib, Jason, et al.
Publicado: (2023)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Comprehensive mastocytosis data analysis from a single center
por: Tiryaki, Tarık Onur, et al.
Publicado: (2023)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Insights in Anaphylaxis and Clonal Mast Cell Disorders
por: González-de-Olano, David, et al.
Publicado: (2017)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features
por: Muñoz-García, Noemí, et al.
Publicado: (2020)

Ex vivo identification and characterization of a population of CD13(high) CD105(+) CD45(−) mesenchymal stem cells in human bone marrow
por: Muñiz, Carmen, et al.
Publicado: (2015)

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
por: Gotlib, Jason, et al.
Publicado: (2021)

499 Mastocytosis: Importance as Differential Diagnosis in Skin Diseases. Report of Two Cases
por: Gonzalez-Carsolio, Aida, et al.
Publicado: (2012)

Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)

Cutaneous mastocytosis in childhood
por: Nemat, Katja, et al.
Publicado: (2022)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Clinical challenge for gastroenterologists–Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review
por: Elvevi, Alessandra, et al.
Publicado: (2022)

Gene Therapy for Acquired and Genetic Cholestasis
por: Martínez-García, Javier, et al.
Publicado: (2022)

Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management
por: Crupi, Francesca, et al.
Publicado: (2022)

Association between Genetic Subgroups of Pancreatic Ductal Adenocarcinoma Defined by High Density 500 K SNP-Arrays and Tumor Histopathology
por: Gutiérrez, María Laura, et al.
Publicado: (2011)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis
por: Jain, Preetesh, et al.
Publicado: (2017)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis
por: Riffel, Philipp, et al.
Publicado: (2020)

An elusive case of systemic mastocytosis
por: Lee, JK, et al.
Publicado: (2010)

Mastocytosis in the skin in children and adults
por: Lange, Magdalena
Publicado: (2015)

Targeted Treatment Options in Mastocytosis
por: Vaes, Mélanie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v8jjkiv30e3bua45568hh62e35